StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio operating margin

Operating margin is operating income as a percentage of revenue.

Regenxbio's operating margin for the twelve months ending Jun 30, 2026 was -94.1%. For fiscal 2025 it was -94.6%, against -280.0% the year before. The highest annual figure on record is 40.3% in fiscal 2018.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-94.6%+185.5
FY2024Dec 31, 2024-280.0%+17.1
FY2023Dec 31, 2023-297.1%−63.9
FY2022Dec 31, 2022-233.2%−267.2
FY2021Dec 31, 202134.0%+111.2
FY2020Dec 31, 2020-77.1%+345.8
FY2019Dec 31, 2019-422.9%−463.2
FY2018Dec 31, 201840.3%+770.5
FY2017Dec 31, 2017-730.2%+693.7
FY2016Dec 31, 2016-1423.8%−1118.9
FY2015Dec 31, 2015-304.9%−244.8
FY2014Dec 31, 2014-60.2%+18.3
FY2013Dec 31, 2013-78.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202627.1%+323.3
Q1 FY2026Mar 31, 2026-1304.0%−1317.6
Q4 FY2025Dec 31, 2025-190.0%+52.2
Q3 FY2025Sep 30, 2025-176.3%+80.3
Q2 FY2025Jun 30, 2025-296.3%−44.9
Q1 FY2025Mar 31, 202513.6%+422.4
Q4 FY2024Dec 31, 2024-242.1%+45.5
Q3 FY2024Sep 30, 2024-256.6%−31.9
Q2 FY2024Jun 30, 2024-251.3%+114.6
Q1 FY2024Mar 31, 2024-408.8%−63.1
Q4 FY2023Dec 31, 2023-287.7%−103.4
Q3 FY2023Sep 30, 2023-224.7%+43.3
Q2 FY2023Jun 30, 2023-366.0%−174.4
Q1 FY2023Mar 31, 2023-345.7%−23.8
Q4 FY2022Dec 31, 2022-184.3%−263.0
Q3 FY2022Sep 30, 2022-268.0%−81.6
Q2 FY2022Jun 30, 2022-191.5%+45.5
Q1 FY2022Mar 31, 2022-321.9%−88.7
Q4 FY2021Dec 31, 202178.7%+328.8
Q3 FY2021Sep 30, 2021-186.4%−200.5
Q2 FY2021Jun 30, 2021-237.0%+15.5
Q1 FY2021Mar 31, 2021-233.2%−19.6
Q4 FY2020Dec 31, 2020-250.2%+92.5
Q3 FY2020Sep 30, 202014.1%+258.3
Q2 FY2020Jun 30, 2020-252.5%+215.3
Q1 FY2020Mar 31, 2020-213.7%+3848.1
Q4 FY2019Dec 31, 2019-342.7%−348.7
Q3 FY2019Sep 30, 2019-244.2%+184.1
Q2 FY2019Jun 30, 2019-467.9%−483.7
Q1 FY2019Mar 31, 2019-4061.8%−4138.8
Q4 FY2018Dec 31, 20186.0%+819.6
Q3 FY2018Sep 30, 2018-428.3%+1166.7
Q2 FY2018Jun 30, 201815.9%+245.3
Q1 FY2018Mar 31, 201877.1%+5114.9
Q4 FY2017Dec 31, 2017-813.6%+393.3
Q3 FY2017Sep 30, 2017-1595.0%+13339.4
Q2 FY2017Jun 30, 2017-229.4%–
Q1 FY2017Mar 31, 2017-5037.8%–
Q4 FY2016Dec 31, 2016-1206.9%–
Q3 FY2016Sep 30, 2016-14934.4%–

More Regenxbio figures

See a number that looks wrong?